Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline ...
Combining the direct cytotoxic effects of antibody-drug conjugates (ADCs) with the immune-enhancing properties of immunostimulators represents a new therapeutic strategy that could not only eradicate ...
While ADC development is accelerating rapidly, researchers need more sophisticated tools to evaluate ADC efficacy and tumor penetration in models that better reflect the complex tumor ...